<DOC>
	<DOCNO>NCT00322751</DOCNO>
	<brief_summary>Given activity single-agent Topotecan NSCLC , scientific rationale medical interest study agent combination radiation . In addition , Topotecan administer weekly basis offer advantage daily x 5 regimen , i.e. , convenience administration few visit clinic .</brief_summary>
	<brief_title>Concurrent Radiotherapy With Weekly Topotecan Primary Treatment Inoperable Localized Non-small Cell Lung Cancer</brief_title>
	<detailed_description>This study chemoradiation patient inoperable non small cell lung cancer poor pulmonary function . These patient usually limited treatment option compromise lung function . Chemoradiation usually superior radiation alone , extensively test patient population . Topotecan drug approve lung cancer synergistic activity radiation . The study determine safest dose topotecan use radiation patient population</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Patients histologically proven nonsmall cell lung cancer Stage I IIIA . Inoperable lung cancer poor respiratory lung function , medical reason , determine thoracic surgeon . PS &lt; 2 Age &gt; 18 year Life expectancy &gt; 12 week Normal hematologic , liver , renal function No metastatic disease determine CTPET scan bone scan . No brain metastasis MRI No contraindication radiotherapy Patients uncontrolled CNS metastasis . Active systemic infection . Serious , uncontrolled intercurrent medical psychiatric illness . Secondary active primary malignancy . Inability comply requirement study . Any metastasis outside mediastinum Histologically positive pleural pericardial effusion Any chemotherapy within five year prior enrollment protocol Prior radiotherapy administer chest Women pregnant lactate FEV1 &lt; 1 liter/minute</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>